Concepedia

Helmut Mett

HM

Statistics

Publications

51

Citations

5.1K

H-Index

31

Active since

1980

Affiliations

Novartis (Switzerland)(Current)

University of Basel

Drug Discovery Laboratory (Norway)

Helmut Mett is an author at Novartis (Switzerland) specializing in pharmacology, enzyme inhibition, and medicinal chemistry.

Publications per year

1980–2005

51

Publications

51

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al. · PubMed · 1996 · 1.1K citations

, , +17

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

, , +16

Different Susceptibility of Protein Kinases to Staurosporine Inhibition

Flavio Meggio, Arianna Donella Deana, Maria Ruzzene et al. · European Journal of Biochemistry · 1995 · 291 citations · Full text

, , +13

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al. · Proceedings of the National Academy of Sciences · 1995 · 269 citations · Full text

, , +14

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

J. Zimmermann, Elisabeth Buchdunger, Helmut Mett et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 245 citations

, , +10

1–5 of 51